Marine Oil from C. finmarchicus Enhances Glucose Homeostasis and Liver Insulin Resistance in Obese Prediabetic Individuals

Uloženo v:
Podrobná bibliografie
Název: Marine Oil from C. finmarchicus Enhances Glucose Homeostasis and Liver Insulin Resistance in Obese Prediabetic Individuals
Autoři: Milena Burhop, Jan Philipp Schuchardt, Josefine Nebl, Mattea Müller, Ralf Lichtinghagen, Andreas Hahn
Zdroj: Nutrients
Nutrients; Volume 14; Issue 2; Pages: 396
Informace o vydavateli: MDPI AG, 2022.
Rok vydání: 2022
Témata: Blood Glucose, Male, 2. Zero hunger, 0301 basic medicine, Middle Aged, Article, Body Mass Index, 3. Good health, Copepoda, Placebos, Prediabetic State, 03 medical and health sciences, Dietary Fats, Unsaturated, Double-Blind Method, Liver, Fatty Acids, Omega-3, Animals, Homeostasis, Humans, prediabetes, intermediate hyperglycaemia, glucose metabolism, insulin resistance, marine oil, inflammation, Female, Obesity, Insulin Resistance, Aged
Popis: The intermediate state between normal glucose tolerance and overt type 2 diabetes mellitus is associated with micro- and macrovascular diseases, requiring safe and cost-effective treatment measures interventions. A novel source of LC n-3 FAs is Calanus finmarchicus Oil, which showed promising effects on glucose homeostasis in preclinical studies due to anti-obesity effects and/or anti-inflammatory properties. In total, 43 obese patients (BMI: 31.7 ± 5.2 kg/m2) were allocated in the following two groups: (1) Calanus oil group (2 g CO/day) and (2) placebo group (2 g paraffin oil/day). Markers of glucose metabolism, body composition and energy intake were measured at the beginning (t0), after 12 weeks (t12) and 16 weeks (t16). Overall, parameters reflecting abnormal glucose homeostasis and insulin resistance in the liver, including fasting insulin (−2.9 mU/L ± 4.10, p < 0.05), HOMA-IR (−0.9 ± 1.28, p < 0.05) and hepatic insulin resistance index (−1.06 ± 1.72 × 106, p < 0.05) significantly enhanced after a 12-week CO-intervention, while no differences were observed in HbA1c, AUC0–2h Glucose, AUC0–2h Insulin, 2 h plasma glucose and muscle insulin sensitivity index. Our results indicate that Calanus oil causes beneficial effects on glucose metabolism and insulin resistance in obese patients, with clinical relevance to be verified in further studies. In addition, the possible active compounds and their mechanisms of action should be elucidated.
Druh dokumentu: Article
Other literature type
Popis souboru: application/pdf
Jazyk: English
ISSN: 2072-6643
DOI: 10.3390/nu14020396
Přístupová URL adresa: https://www.mdpi.com/2072-6643/14/2/396/pdf
https://pubmed.ncbi.nlm.nih.gov/35057577
Rights: CC BY
Přístupové číslo: edsair.doi.dedup.....2b55dc2b7f949531a0ab2c379b067b1e
Databáze: OpenAIRE
Nepřihlášeným uživatelům se plný text nezobrazuje
Popis
Abstrakt:The intermediate state between normal glucose tolerance and overt type 2 diabetes mellitus is associated with micro- and macrovascular diseases, requiring safe and cost-effective treatment measures interventions. A novel source of LC n-3 FAs is Calanus finmarchicus Oil, which showed promising effects on glucose homeostasis in preclinical studies due to anti-obesity effects and/or anti-inflammatory properties. In total, 43 obese patients (BMI: 31.7 ± 5.2 kg/m2) were allocated in the following two groups: (1) Calanus oil group (2 g CO/day) and (2) placebo group (2 g paraffin oil/day). Markers of glucose metabolism, body composition and energy intake were measured at the beginning (t0), after 12 weeks (t12) and 16 weeks (t16). Overall, parameters reflecting abnormal glucose homeostasis and insulin resistance in the liver, including fasting insulin (−2.9 mU/L ± 4.10, p < 0.05), HOMA-IR (−0.9 ± 1.28, p < 0.05) and hepatic insulin resistance index (−1.06 ± 1.72 × 106, p < 0.05) significantly enhanced after a 12-week CO-intervention, while no differences were observed in HbA1c, AUC0–2h Glucose, AUC0–2h Insulin, 2 h plasma glucose and muscle insulin sensitivity index. Our results indicate that Calanus oil causes beneficial effects on glucose metabolism and insulin resistance in obese patients, with clinical relevance to be verified in further studies. In addition, the possible active compounds and their mechanisms of action should be elucidated.
ISSN:20726643
DOI:10.3390/nu14020396